Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zymeworks Inc.    ZYME   CA98985W1023

ZYMEWORKS INC.

(ZYME)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
54.68(c) 52.86(c) 51.47(c) 51.93(c) 52.16(c) Last
316 600 583 536 572 530 447 460 417 672 Volume
-1.35% -3.33% -2.63% +0.89% +0.44% Change
More quotes
Financials (USD)
Sales 2020 30,7 M - -
Net income 2020 -199 M - -
Net cash position 2020 272 M - -
P/E ratio 2020 -12,9x
Yield 2020 -
Sales 2021 34,7 M - -
Net income 2021 -253 M - -
Net cash position 2021 139 M - -
P/E ratio 2021 -10,8x
Yield 2021 -
Capitalization 2 397 M 2 397 M -
EV / Sales 2020 69,2x
EV / Sales 2021 65,1x
Nbr of Employees 325
Free-Float 80,5%
More Financials
Company
Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink,... 
More about the company
Notations Surperformance© of Zymeworks Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ZYMEWORKS INC.
01/18ZYMEWORKS : Zanidatamab Data Highlight Durable Antitumor Activity in HER2-Expres..
AQ
01/15ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
01/15ZYMEWORKS : Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑..
BU
01/11ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
01/11ZYMEWORKS : Highlights 2020 Achievements and Announces Corporate Priorities
BU
01/07ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
01/07ZYMEWORKS : to Present at J.P. Morgan Healthcare Conference and Host Two Webcast..
BU
2020IMMUNOPRECISE ANTIBODIES : Collaboration Enables Preclinical Manufacturing of Le..
AQ
2020ZYMEWORKS : Zanidatamab Clinical Data Selected for Oral Presentation at the Amer..
AQ
2020ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
2020ZYMEWORKS : Zanidatamab Clinical Data Selected for Oral Presentation at the Amer..
BU
2020ZYMEWORKS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020EXELIXIS : In-Licenses Iconic Therapeutics Tissue Factor-Targeting Antibody-Drug..
AQ
2020ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
2020Exelixis to Take Over Targeted Cancer Treatment Program From Iconic Therapeut..
MT
More news
News in other languages on ZYMEWORKS INC.
2020ZYMEWORKS : obtient la désignation de médicament orphelin de la Commission europ..
2020ZYMEWORKS : erhält Orphan-Drug-Status von der Europäischen Kommission für den ge..
More news
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | ZYME | CA98985W1023 | MarketScreener
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 60,08 $
Last Close Price 52,16 $
Spread / Highest target 41,9%
Spread / Average Target 15,2%
Spread / Lowest Target -19,5%
EPS Revisions
Managers and Directors
NameTitle
Ali Tehrani President, Chief Executive Officer & Director
Lota S. Zoth Chairman
Neil Klompas Chief Financial Officer & EVP-Business Operations
Surjit Bhimarao Dixit Vice President-Technology
Diana F. Hausman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZYMEWORKS INC.10.37%2 397
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148